TORONTO, Nov. 07, 2018 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSXV: LABS) (the “Company” or “MediPharm Labs”) is pleased to announce that it has reached a significant milestone by completing the purification and production of 150,000 g of cannabis extract. Since concluding its Health Canada sales inspection on September 24, MediPharm Labs has commenced daily production and has achieved our first cannabis oil production target ahead of schedule using critical CO2 extraction and secondary purification processes. This is a Canadian leading volume.
MediPharm Labs is becoming a global leader in pharmaceutical-grade cannabis concentrates. With laser focus, we are executing on that goal, producing at high rates of efficiency, quality, and purity in our operations.
Pat McCutcheon, President and CEO of MediPharm Labs
Since legalization in Canada, the demand for purified cannabis oil is high and trending higher from both medical patients and adult consumers. We are ready to service this market and are building for the future when advanced derivative products will be formulated with concentrates and isolates.
MediPharm Labs is a first-mover in Canadian cannabis oil production and runs three concurrent supercritical CO2 extraction lines within its wholly-owned laboratory and facilities built to cGMP and ISO standards. This phase one of its operations has remaining capacity to significantly increase these throughput volumes, to a total estimated 100,000 kg (100,000,000 g) of dried cannabis annually. MediPharm Labs is moving aggressively on its funded Phase two expansion having taken receipt of two additional supercritical CO2 extractors for use in January 2019. The complete MediPharm Labs phase two expansion is on track to complete by Q2 2019.
MediPharm Labs has partnered with its suppliers to modify equipment for proprietary results. It has been building a stellar team of operators from across complimenting industries such as pharmaceuticals, consumer packaged goods and nutraceuticals. MediPharm Labs will continue to build on this foundation to remain global leaders in cannabis concentrate manufacturing and innovation.
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulations (ACMPR) without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage. MediPharm Labs is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm Labs provides B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate international growers, supplying integrity-assured cannabis oil to qualified companies for sale under their own brand. In addition, MediPharm Labs will supply raw materials, formulations, processing and packaging for the creation of ready-to-sell advanced derivative products.
Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.